ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SKYE Skye Bioscience Inc

11.00
0.22 (2.04%)
Last Updated: 15:20:33
Delayed by 15 minutes
Share Name Share Symbol Market Type
Skye Bioscience Inc NASDAQ:SKYE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.22 2.04% 11.00 10.87 11.00 11.07 10.20 10.66 31,576 15:20:33

Skyepharma PLC - Board Change

18/11/2009 7:00am

Marketwired


Skye Bioscience (NASDAQ:SKYE)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Skye Bioscience Charts.


SKYEPHARMA PLC - BOARD CHANGE - CHAIRMAN

LONDON, UK, 18 November, 2009 - SkyePharma PLC (LSE: SKP) regrets to
announce today that its Chairman, Jeremy Scudamore, has informed the
Board that he intends to step down from the Board at the end of 2009
for health reasons.

Frank Condella, Non-Executive Director and former CEO of
SkyePharma, has agreed to take over as Non-Executive Chairman with
effect from 1 January 2010.

Dr Ken Cunningham, CEO of SkyePharma, commented: "The Board thanks
Jeremy for his valuable contribution as Chairman of the Company since
October 2007 and wishes him a speedy and successful recovery.  We are
very fortunate that Frank Condella is able to take over from Jeremy as
Chairman of SkyePharma. Frank will bring a strong sense of continuity
to the position as well as a deep understanding of the business and we
all look forward to continuing to work with him in his new role."

Editors' Note

Frank Condella was Chief Executive Officer of SkyePharma PLC from 1
March 2006 until 1 September 2008 and has been a Non-Executive Director
since 1 November 2008.  Aged 55, Frank Condella is a Non-Executive
Director of Fulcrum Pharma plc and an independent Director of Columbia
Laboratories, Inc. Previously, he was President of European Operations
at IVAX, Chief Executive officer of Faulding Pharmaceutical Co.,
Vice-President of the Specialty Care Products business at Roche and
Vice-President and General Manager of the Lederle unit of American Home
Products.

For further information please contact:

SkyePharma PLC

Ken Cunningham, Chief Executive Officer       +44 207 491 1777
Peter Grant, Chief Financial Officer

Financial Dynamics
Jonathan Birt/Susan Quigley                   +44 207 831 3113

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of known molecules to provide a clinical advantage and
life-cycle extension. The Group has twelve approved products in the
areas of oral, inhalation and topical delivery. The Group's products
are marketed throughout the world by leading pharmaceutical companies.
For more information, visit www.skyepharma.com.


                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com

1 Year Skye Bioscience Chart

1 Year Skye Bioscience Chart

1 Month Skye Bioscience Chart

1 Month Skye Bioscience Chart

Your Recent History

Delayed Upgrade Clock